Kailera Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Welcome, everyone, to Jefferies Global Healthcare Conference in London. My name is Roger Song, one of the Senior Analysts cover SMidCap Biotech. It is my pleasure to have a fireside chat with our next company, Kailera, CEO Ron Renaud.
Thanks, Roger. Good to be here.
Excellent. All right. Before we dive in, a lot of different topics across your assets. Can you give us a state of art of Kailera today, and then why you are excited about that 2027?
Yeah. I mean, 2026 has been a year for us of significant execution. We started the first part of the year with a very successful IPO, which helped us fortify the balance sheet. One of the things that we talked about on the roadshow for the IPO was four things that we really wanted to accomplish in 2026 that we thought would set us up really, really well for 2027 and beyond. There were four main things. The lead program is ribupatide. This is our lead dual agonist, GLP-1, GIP dual agonist. We love this program because, first of all, we have an injectable version of this, and we have an oral version of the exact same drug.
We wanted to make sure that we accomplished this year was, we initiated a significant phase III program back in 2024, and in 2025, 2026, sorry, we started in 2025. 2026, we wanted to make sure that we completed enrollment. We were able to do that. More than 5,000 patients globally, 11 countries. I think a lot of our competitors set up studies that are run specifically here in the U.S. This is a truly global trial. We were able to announce the completion of enrollment in that study, in that KaiNETIC-3 program very recently. Second to that was, as I mentioned, we have the oral version of that exact same peptide right behind that. One of the significant goals there was to get line of sight from the U.S. regulators to start a phase III program with that.
Recently, we held our end of phase II program with the U.S. FDA and got a green light to move forward on that. That program will start in the first half of next year, and we're very, very excited about the oral peptide program. Behind that, we've got an oral small molecule we call safiglipron. We started a significant phase II study with that program back in the first quarter of this year. That has also completed enrollment. We also wanted to get line of sight on a U.S. IND for our triple G KAI-4729, and we recently got that IND cleared, and KAI-4729 will start phase I studies before the end of this year. Clearly progress across all four programs that we have. All four programs are now under U.S. INDs. This is very, very important.
To have the phase III oral peptide program starting in the first half of next year is great for us. That really starts to set us up for 2027, where we get our first look at data from in our hands of safiglipron, our oral small molecule. That phase II data should read out sometime in the middle of next year. We also have a phase II-B high-dose study that we're looking at with our injectable ribupatide program. That'll read out in the middle of next year. Then, of course, our phase I triple G KAI-4729 will read out sometime next year as well. Our global phase III program should read out sometime in the middle of 2028. As you can imagine, that's a much bigger study, a much longer duration of treatment.
While this is all going on at Kailera, our colleagues at Hengrui are also generating a significant amount of data, and they'll have data readouts as well for a number of the programs that are under the exact same products that we're developing at Kailera.
Excellent. Thanks, Ron. All right. I know the key value driver here is ribupatide in both injectable and oral form. Maybe focus on the injectable for a moment. Understanding your partner in China, Hengrui, generally already positive phase III for the eight mg kind of dose, and then your phase III right now, KaiNETIC- Yes KaiNETIC, for the top dose is 10 milligrams.
How should we think about that profile when you read out the phase III? What's your target? Because right now, the space is crowded, but also you potentially have the best compound out there.
Yeah. I think first of all, if we just go back to the very basis of the ribupatide program, our colleagues at Hengrui really designed this molecule to be more potent. Right out of the gate, they designed it to be more potent than Lilly's tirzepatide. It has greater GLP-1 activity, about three times the GLP-1 activity when you compare it to tirzepatide. It's got a longer half-life. It's got about a seven-day half-life. It has all of the features that should give it the qualities to generate greater weight loss. In fact, as you point out, at eight milligrams, our colleagues at Hengrui were able to show about 23.7% weight loss. This is significantly higher than what we've seen at almost twice the dose with Lilly's program. We're super excited about that.
The data is already, it gives us a lot of encouragement that we should see significant weight loss. That was at eight milligrams. As you point out, the phase III is going to go up to 10. While the BMIs are lower, BMI is not really what drives the weight loss, whether it's higher BMIs or lower BMIs. It's more around gender. With these studies being run here in the U.S. and globally, there will be more females on the study than what we've probably seen in the Chinese study. That gives us a lot of optimism that the data that we've already seen, the very, very encouraging data that we've already seen in terms of weight loss, should continue to play out not only at eight milligrams, but at 10 milligrams.
We have, as we mentioned, an ongoing study looking at even higher doses.
Yeah. Awesome. So for the KaiNETIC-3, you do have an open-label semaglutide arm. So tell us why you want to add that arm, and what's the goal there, and how much delta or the superiority you want to achieve in that arm?
Yeah. So, we do have a study. In our phase III study, KaiNETIC-3 is looking at BMIs above 35, and we're also looking at higher doses. But we're also doing a head-to-head study directly against semaglutide 2.4 milligrams. The reason for that is, as we think about the payer environment when we expect to launch our drug, semaglutide is the first drug that will lose exclusivity. So as we really think about the step through, what the payers are going to have to think about as they choose to pay for these therapeutics, we wanted to take that off the table directly. You ask about what kind of difference we expect to see. We're not going to clarify what difference is, but it's a significant, it's a big enough study. It's statistically powered to show a significant difference.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
